Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway
- PMID: 37989907
- DOI: 10.1007/s00535-023-02052-0
Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway
Abstract
Background: Although the serrated-neoplasia pathway reportedly accounts for 15-30% of colorectal cancer (CRC), no studies on chemoprevention of sessile serrated lesions (SSLs) have been reported. We searched for effective compounds comprehensively from a large series of compounds by employing Connectivity Map (CMAP) analysis of SSL-specific gene expression profiles coupled with in vitro screening using SSL patient-derived organoids (PDOs), and validated their efficacy using a xenograft mouse model of SSL.
Methods: We generated SSL-specific gene signatures based on DNA microarray data, and applied them to CMAP analysis with 1309 FDA-approved compounds to select candidate compounds. We evaluated their inhibitory effects on SSL-PDOs using a cell viability assay. SSL-PDOs were orthotopically transplanted into NOG mice for in vivo evaluation. The signal transduction pathway was evaluated by gene expression profile and protein expression analysis.
Results: We identified 221 compounds by employing CMAP analysis of SSL-specific signatures, which should cancel the gene signatures, and narrowed them down to 17 compounds. Cell viability assay using SSL-PDOs identified lansoprazole as having the lowest IC50 value (47 µM) among 17 compounds. When SSL-PDO was orthotopically transplanted into murine intestinal tract, the tumor grew gradually. Administration of lansoprazole to mice inhibited the growth of SSL xenograft whereas the tumor in control mice treated with vehicle alone grew gradually over time. The Ki67 index in xenograft lesions from the lansoprazole group was significantly lower compared with the control group. Cell cycle analysis of SSL-PDOs treated with lansoprazole exhibited a significant increase in G1 phase cell population. Microarray and protein analysis revealed that lansoprazole downregulated Skp2 expression and upregulated p27 expression in SSL-PDOs.
Conclusions: Our data strongly suggest that lansoprazole is the most effective chemopreventive agent against SSL, and that lansoprazole induces G1 cell cycle arrest by downregulating Skp2 and upregulating p27 in SSL cells.
Keywords: Chemoprevention; Connectivity map; Lansoprazole; Organoid; Sessile serrated lesion.
© 2023. Japanese Society of Gastroenterology.
Similar articles
-
Resveratrol inhibits development of colorectal adenoma via suppression of LEF1; comprehensive analysis with connectivity map.Cancer Sci. 2022 Dec;113(12):4374-4384. doi: 10.1111/cas.15576. Epub 2022 Sep 20. Cancer Sci. 2022. PMID: 36082704 Free PMC article.
-
Aberrant PRDM2 methylation as an early event in serrated lesions destined to evolve into microsatellite-instable colorectal cancers.J Pathol Clin Res. 2024 Mar;10(2):e348. doi: 10.1002/cjp2.348. J Pathol Clin Res. 2024. PMID: 38380944 Free PMC article.
-
Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids.J Exp Clin Cancer Res. 2023 Jul 17;42(1):170. doi: 10.1186/s13046-023-02754-6. J Exp Clin Cancer Res. 2023. PMID: 37460938 Free PMC article.
-
Sessile serrated lesions: Clinicopathological characteristics, endoscopic diagnosis, and management.Dig Endosc. 2022 Sep;34(6):1096-1109. doi: 10.1111/den.14273. Epub 2022 Mar 29. Dig Endosc. 2022. PMID: 35352394 Review.
-
Sessile serrated lesions with dysplasia: is it possible to nip them in the bud?J Gastroenterol. 2023 Aug;58(8):705-717. doi: 10.1007/s00535-023-02003-9. Epub 2023 May 23. J Gastroenterol. 2023. PMID: 37219625 Free PMC article. Review.
Cited by
-
Single-Cell Dissection of the Serrated Pathway: Cellular Heterogeneity and Genetic Causality in Colorectal Cancer.Int J Mol Sci. 2025 Jul 25;26(15):7187. doi: 10.3390/ijms26157187. Int J Mol Sci. 2025. PMID: 40806320 Free PMC article.
-
Organoids in gastrointestinal diseases: from bench to clinic.MedComm (2020). 2024 Jun 29;5(7):e574. doi: 10.1002/mco2.574. eCollection 2024 Jul. MedComm (2020). 2024. PMID: 38948115 Free PMC article. Review.
-
Cancer pathways in serrated polyposis syndrome: is conventional more crucial than serrated?J Gastroenterol. 2025 Jan;60(1):127-128. doi: 10.1007/s00535-024-02177-w. Epub 2024 Nov 16. J Gastroenterol. 2025. PMID: 39549067 No abstract available.
References
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–32. - PubMed
-
- Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–100. - PubMed
-
- Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1–10. - PubMed
-
- Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol. 2013;11:760–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous